News: CBE

Drug industry’s carbon impact could be cut by half

In a first-of-its-kind analysis, Cornell researchers and partners at the Clinton Health Access Initiative found that pharmaceutical producers could reduce their environmental impact by roughly half by optimizing manufacturing processes and supply chain networks and by switching to renewable energy sources. Read more

DeLisa's work highlighted in a Nature technology feature

A recent technology feature in the journal Nature highlighted the work of CBE Professor Matt DeLisa, the William L. Lewis Professor of Engineering and Director of the Cornell Institute of Biotechnology. The story, “How cell-free processes could speed up vaccine development,” discusses the ongoing efforts of bioengineers, including DeLisa and his team, to discover cheaper and easier ways to make proteins and other complex biomolecules. Antibodies, for instance, have become the bread and butter for many pharmaceutical companies, and DeLisa says that the ability to synthesize these molecules... Read more